Dual Medical Insurance and Commercial Insurance Drug Catalogs to Take Effect in 2026: Innovative Drug Payment System Enters an Era of Tiered Coverage

nashnova research
今天发布阅读约 11 分钟

China's national health insurance authority released dual 2026 catalogues — basic medical insurance and commercial health insurance — adding 107 drugs including a record 51 Class-1 innovative drugs, marking a structural shift from volume-for-price toward tiered, value-driven drug reimbursement.

01

What do the "dual catalogues" actually change?

Previously, innovative drugs had one path: cut price, enter national insurance, trade volume for margin. Now there are two payment tiers — basic insurance covers essential drugs; the commercial catalogue covers high-cost innovations.
This means → an expensive therapy no longer has to slash its price just to get in the door. It can first gain coverage through the commercial tier, then migrate into basic insurance over time.
In plain terms = China's drug reimbursement system went from one lane to two. Expensive drugs now have someone to foot the bill.
02

How did CAR-T and gene therapies break through the payment barrier?

Carsgen Therapeutics' Shurui-ji-ao-lun-sai injection entered the commercial catalogue — the world's first solid-tumor CAR-T drug, approved in June 2026.
Belief BioMed's Bo-pie-da-ke-ji injection was included simultaneously — China's first approved gene-therapy drug, treating moderate-to-severe hemophilia B.
The reverse path matters more: JW Therapeutics' Rui-ji-ao-lun-sai transferred from the commercial catalogue into basic insurance, becoming the first CAR-T drug in China's national basic insurance catalogue — after already covering 105 cities' Huiminbao plans and nearly 100 commercial health-insurance products.
This reflects that the commercial catalogue is not a parking lot — it is a stepping stone into basic insurance, and this pathway has now been validated for the first time.
03

Which drugmakers benefit most directly?

Hengrui Medicine has 11 products involved in new inclusions, expanded indications, or renewals. Combined 2025 sales for these products approached RMB 7 billion.
Innovent Biologics had 7 products included. Its blockbuster GLP-1/GCG dual-agonist mazdutide (obesity + diabetes) gained first-time access; 17 of 20 marketed products are now in the national insurance catalogue.
Junshi Biosciences' PD-1 drug toripalimab added a new indication. All 13 approved indications in mainland China now have full insurance coverage.
04

What does this mean for smaller, early-stage drug companies?

In the past, a new drug took two to three years from approval to insurance listing to hospital stocking to meaningful sales. That cycle is now sharply compressed.
In plain terms = BeiGene partner Baili-Tianheng's lun-kang-yi-long-tuo monoclonal antibody was approved for nasopharyngeal cancer in 2026 and completed insurance entry the same year — listed in the catalogue the year it launched.
This means → the commercialization "ramp-up" for innovative-drug companies is shorter, revenue arrives faster, and that matters most to cash-tight smaller firms.
05

Is the commercial catalogue actually working on the ground?

By end-October 2026, 18 drugs from the 2025 commercial catalogue were stocked at 1,710 institutions, generating cumulative sales of roughly RMB 600 million. The number of stocking institutions grew about 140% from pre-listing levels.
The 2026 basic insurance catalogue included 16 innovative drugs for the first time and set explicit stocking requirements for public hospitals at all levels.
This means → the last mile — from "listed in the catalogue" to "available at the hospital, reimbursable by insurance" — is being connected. But whether institutional rollout can keep pace with drugmakers' sales expectations remains the key test for the next phase.

市场有风险,内容仅供研究参考,不构成投资建议。